OBJECTIVE: To quantify the plausible contribution of prostate-specific antigen (PSA) screening to the nearly 30% decline in the US prostate cancer mortality rate observed during the 1990s. METHODS: Two mathematical modeling teams of the US National Cancer Institute's Cancer Intervention and Surveillance Modeling Network independently projected disease mortality in the absence and presence of PSA screening. Both teams relied on Surveillance, Epidemiology, and End Results (SEER) registry data for disease incidence, used common estimates of PSA screening rates, and assumed that screening, by shifting disease from distant to local-regional clinical stage, confers a corresponding improvement in disease-specific survival. RESULTS: The teams projected similar mortality increases in the absence of screening and decreases in the presence of screening after 1985. By 2000, the models projected that 45% (Fred Hutchinson Cancer Research Center) to 70% (University of Michigan) of the observed decline in prostate cancer mortality could be plausibly attributed to the stage shift induced by screening. CONCLUSIONS: PSA screening may account for much, but not all, of the observed drop in prostate cancer mortality. Other factors, such as changing treatment practices, may also have played a role in improving prostate cancer outcomes.
OBJECTIVE: To quantify the plausible contribution of prostate-specific antigen (PSA) screening to the nearly 30% decline in the US prostate cancer mortality rate observed during the 1990s. METHODS: Two mathematical modeling teams of the US National Cancer Institute's Cancer Intervention and Surveillance Modeling Network independently projected disease mortality in the absence and presence of PSA screening. Both teams relied on Surveillance, Epidemiology, and End Results (SEER) registry data for disease incidence, used common estimates of PSA screening rates, and assumed that screening, by shifting disease from distant to local-regional clinical stage, confers a corresponding improvement in disease-specific survival. RESULTS: The teams projected similar mortality increases in the absence of screening and decreases in the presence of screening after 1985. By 2000, the models projected that 45% (Fred Hutchinson Cancer Research Center) to 70% (University of Michigan) of the observed decline in prostate cancer mortality could be plausibly attributed to the stage shift induced by screening. CONCLUSIONS:PSA screening may account for much, but not all, of the observed drop in prostate cancer mortality. Other factors, such as changing treatment practices, may also have played a role in improving prostate cancer outcomes.
Authors: W F Gee; H L Holtgrewe; M L Blute; B J Miles; M J Naslund; R E Nellans; M P O'Leary; R Thomas; M R Painter; J J Meyer; T J Rohner; T P Cooper; R Blizzard; R B Fenninger; L Emmons Journal: J Urol Date: 1998-11 Impact factor: 7.450
Authors: Pamela A Shaw; Ruth Etzioni; Steven B Zeliadt; Angela Mariotto; Kent Karnofski; David F Penson; Noel S Weiss; Eric J Feuer Journal: Am J Epidemiol Date: 2004-12-01 Impact factor: 4.897
Authors: John Concato; Carolyn K Wells; Ralph I Horwitz; David Penson; Graeme Fincke; Dan R Berlowitz; Gregory Froehlich; Dawna Blake; Martyn A Vickers; Gerald A Gehr; Nabil H Raheb; Gail Sullivan; Peter Peduzzi Journal: Arch Intern Med Date: 2006-01-09
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Ruth Etzioni; David F Penson; Julie M Legler; Dante di Tommaso; Rob Boer; Peter H Gann; Eric J Feuer Journal: J Natl Cancer Inst Date: 2002-07-03 Impact factor: 13.506
Authors: Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto Journal: Diagn Interv Radiol Date: 2014 Jul-Aug Impact factor: 2.630
Authors: Alex Tsodikov; Roman Gulati; Tiago M de Carvalho; Eveline A M Heijnsdijk; Rachel A Hunter-Merrill; Angela B Mariotto; Harry J de Koning; Ruth Etzioni Journal: Cancer Date: 2017-04-24 Impact factor: 6.860